Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | S100A4 | P26447 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29769743 | 1.00 | CFTR (0.42) | CFTRGOPCTHRBTDP1SMN1; SMN2 | |
| SCHEMBL11453348 | 0.87 | ALDH1A1 (0.40) | CFTRGOPCTDP1LMNAOPRK1 | |
| SCHEMBL11453227 | 0.87 | CFTR (0.46) | CFTRGOPCTHRBSMN1; SMN2LMNA | |
| SCHEMBL24279299 | 0.83 | PDK2 (0.53) | CFTRGOPCSMN1; SMN2LMNAMAPT | |
| SCHEMBL31003499 | 0.78 | PDK2 (0.42) | LMNAOPRK1PDK2NPSR1 | |
| SCHEMBL23630503 | 0.76 | DNMT1 (0.38) | CFTRGOPCTHRBTDP1SMN1; SMN2 | |
| SCHEMBL7031351 | 0.75 | ALOX5 (0.38) | CFTRGOPCLMNAMEN1KMT2A | |
| SCHEMBL6856706 | 0.74 | CFTR (0.45) | CFTRGOPCTHRBTDP1SMN1; SMN2 | |
| SCHEMBL129053 | 0.74 | MEN1 (0.67) | CFTRGOPCTHRBTDP1SMN1; SMN2 | |
| SCHEMBL29392072 | 0.74 | MEN1 (0.67) | CFTRGOPCTHRBTDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 406 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117623959-A | Synthesis method of threo-3-fluoro-N-9-phenyl-9-fluorene-L-tert-butyl aspartate | 吉尔多肽生物制药(大连市)有限公司 | 2024-03-01 | — | — | CN | claimed |
| CN-113861403-B | Nanometer material and preparation method and application thereof | 北京化工大学 | 2024-01-26 | — | — | CN | claimed |
| CN-104603215-A | Composition for coating high refractive layer and transparent conductive film comprising same | LG HAUSYS LTD | 2015-05-06 | — | — | CN | claimed |
| US-6797745-B1 | Hot melt inks containing styrene or terpene polymers | XEROX CORPORATION | 2004-09-28 | — | — | US | claimed |
| US-20260070945-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2026-03-12 | — | — | US | disclosed |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4644366-A1 | PREPARATION METHODS FOR PILOCARPINE AND INTERMEDIATE COMPOUND THEREOF | Zhejiang Ausun Pharmaceutical Co., Ltd. (CN) | 2025-11-05 | — | — | EP | disclosed |
| US-20250289830-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2025-09-18 | — | — | US | disclosed |
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2025-08-07 | — | — | US | disclosed |
| US-12351591-B2 | KRas inhibitors | ELI LILLY AND COMPANY (US) | 2025-07-08 | — | — | US | disclosed |
| CN-118909031-B | Anti-coronavirus compounds, compositions and uses thereof | 上海柯君医药科技有限公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20250163104-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2025-05-22 | — | — | US | disclosed |
| US-5571825-A | Method of selectively inhibiting prostaglandin G/H synthase-2 | WARNER-LAMBERT COMPANY (US) | 1996-11-05 | — | — | US | disclosed |
| EP-0643710-A1 | SYNTHESIS OF OPTICALLY ACTIVE LACTONES FROM L-ASPARTIC ACID AND INTERMEDIATES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-03-22 | — | — | EP | disclosed |
| CN-1027695-C | Heterocyclic-NMDA antagonists | MERRELL DOW PHARMA (US) | 1995-02-22 | — | — | CN | disclosed |
| CN-1098107-A | modified oligodeoxynucleotides, their preparation and their therapeutic use | SANKYO CO (JP) | 1995-02-01 | — | — | CN | disclosed |
| EP-0611075-A1 | Modified oligodeoxyribonucleotides, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1994-08-17 | — | — | EP | disclosed |
| US-5322942-A | Deprotecting and hydrolyzing protected aspartic acid diester, reacting with nitrosylating agent in presence of hydrogen halide, esterifying, reacting with acyl aryl derivative | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-06-21 | — | — | US | disclosed |
| WO-1992021675-A1 | SYNTHESIS OF OPTICALLY ACTIVE LACTONES FROM L-ASPARTIC ACID AND INTERMEDIATES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1992-12-10 | — | — | WO | disclosed |
| CN-1056499-A | HETEROCYCLIC-NMDA ANTAGONISTS | MERRELL DOW PHARMA (US) | 1991-11-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163104-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | CFTR 2714/4885GOPC 873/4885THRB 3623/4885 |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | CFTR 1664/4885GOPC 266/4885THRB 2562/4885 |
| US-20260070945-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | CFTR 1808/4885GOPC 249/4885THRB 2734/4885 |
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | CFTR 2969/4885GOPC 749/4885THRB 3552/4885 |
| US-12351591-B2 | KRas inhibitors | KRAS, NRAS, HRAS | CFTR 53/4885GOPC 3163/4885THRB 1443/4885 |
| US-20250289830-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | CFTR 53/4885GOPC 3163/4885THRB 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.